GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Mapk9 | increases phosphorylation | EXP | | 6480464 | CTD | Arsenic Trioxide results in increased phosphorylation of MAPK9 protein | PMID:21145380 PMID:27174766 | Mapk9 | multiple interactions | EXP | | 6480464 | CTD | Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein] | PMID:21145380 PMID:27174766 | Mapk9 | increases activity | ISO | MAPK9 (Homo sapiens) | 6480464 | CTD | Arsenic Trioxide results in increased activity of MAPK9 protein | PMID:12296996 | Mapk9 | increases expression | ISO | MAPK9 (Homo sapiens) | 6480464 | CTD | Arsenic Trioxide results in increased expression of MAPK9 protein | PMID:17374990 | Mapk9 | increases phosphorylation | ISO | MAPK9 (Homo sapiens) | 6480464 | CTD | Arsenic Trioxide results in increased phosphorylation of MAPK9 protein | PMID:18412143 PMID:24466103 | Mapk9 | increases phosphorylation | ISO | Mapk9 (Mus musculus) | 6480464 | CTD | Arsenic Trioxide results in increased phosphorylation of MAPK9 protein | PMID:15688020 | Mapk9 | increases response to substance | ISO | MAPK9 (Homo sapiens) | 6480464 | CTD | MAPK9 results in increased susceptibility to Arsenic Trioxide | PMID:20799280 | Mapk9 | increases response to substance | ISO | Mapk9 (Mus musculus) | 6480464 | CTD | MAPK9 protein results in increased susceptibility to Arsenic Trioxide; MAPK9 results in increased susceptibility to Arsenic Trioxide | PMID:16818652 | Mapk9 | multiple interactions | ISO | MAPK9 (Homo sapiens) | 6480464 | CTD | [Bortezomib co-treated with Arsenic Trioxide] affects the expression of MAPK9 protein; [IL24 protein co-treated with Arsenic Trioxide] results in increased phosphorylation of MAPK9 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK9 protein; indole-5-carboxamide promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; MAPK8 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; MAPK9 mutant form inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; MAPK9 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; MAPK9 mutant form inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; SCIO-469 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK9 protein] | PMID:15580305 PMID:16818652 PMID:18412143 PMID:18718063 PMID:20799280 | Mapk9 | multiple interactions | ISO | Mapk9 (Mus musculus) | 6480464 | CTD | [Arsenic Trioxide results in increased abundance of arsenite] which results in increased phosphorylation of MAPK9 protein | PMID:36791901 | |
Go Back to source page | Continue to Ontology report |